BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Group 1 - BriaCell Therapeutics Corp. has completed an underwritten public offering of 3,066,666 units, raising approximately $13.8 million in gross proceeds at a price of $4.50 per unit [1][2] - Each unit consists of one common share (or a pre-funded warrant) and one warrant, with the warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXZ" [1] - The warrants are immediately exercisable at an exercise price of $5.25 per share and expire five years from the date of issuance [1] Group 2 - The net proceeds from the offering will be used for working capital requirements, general corporate purposes, and to advance business objectives [2] - ThinkEquity acted as the sole book-running manager for the offering [2] Group 3 - A registration statement on Form S-1 was filed with the SEC and became effective on April 24, 2025, allowing the offering to proceed [3]